Capricor Therapeutics Inc (OTCMKTS:CAPR) had its price objective increased by equities researchers at HC Wainwright from $2.15 to $6.50 in a research note issued on Friday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the biotechnology company’s stock.

Other equities analysts also recently issued reports about the company. ValuEngine downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Wednesday, August 16th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $2.15 target price on shares of Capricor Therapeutics in a research note on Saturday, July 22nd. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $5.48.

Shares of Capricor Therapeutics (CAPR) traded up 3.09% during mid-day trading on Friday, hitting $1.00. The company had a trading volume of 1,080,117 shares. Capricor Therapeutics has a 12 month low of $0.63 and a 12 month high of $4.00. The firm has a 50-day moving average of $1.07 and a 200-day moving average of $1.74. The company’s market cap is $22.60 million.

Capricor Therapeutics (OTCMKTS:CAPR) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $1.10 million. On average, analysts expect that Capricor Therapeutics will post ($0.70) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Capricor Therapeutics Inc (CAPR) Given New $6.50 Price Target at HC Wainwright” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at

A hedge fund recently raised its stake in Capricor Therapeutics stock. Virtu KCG Holdings LLC increased its stake in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 571.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 179,301 shares of the biotechnology company’s stock after purchasing an additional 152,614 shares during the period. Virtu KCG Holdings LLC owned 0.79% of Capricor Therapeutics worth $149,000 at the end of the most recent reporting period.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.